

Hywel Dda Health Board Formulary

Endocrine system 06.01 - Drugs used in diabetes

Related Documents

NICE guidance on Endocrine, nutritional and metabolic topics

NICE clinical guideline CG87 - Type 2 Diabetes - newer agents (partial update of CG66) - May 2009

NICE clinical guideline CG66 - Type 2 diabetes (partially updated by CG87) - May 2008

NICE clinical guideline CG63 - Diabetes in pregnancy - Mar 2008

NICE clinical guideline CG15 - Type 1 diabetes - Jul 2004

NICE Technology appraisal TA60 - Diabetes (types 1 and 2) - patient education models - Apr 2003

Antibiotic Guidelines for Diabetes Related Foot Infections

Diabetes Care Pathway

06.01.01 - Insulins

All insulin doses must be measured and administered using an insulin syringe or commercial insulin pen device

06.01.01.01 - Short-acting insulins

soluble insulin - Human sequence

S Human Actrapid

S Humulin S

Recombinant human insulin analogue

S Insulin Lispro (Humalog)

S Insulin Aspart (NovoRapid)

S Insulin Glulisine (Apidra)

06.01.01.02 - Intermediate- and long-acting insulins

Non-biphasic Insulins

Isophane insulin - Human sequence

S Humulin I

Insulin detemir

S Levemir

Insulin glargine

S Lantus

Biphasic Insulins
Biphasic isophane insulin - Human sequence

S Humulin M3
S Insuman Comb 25

Biphasic insulin aspart

S Novomix 30

Biphasic insulin lispro

S Humalog Mix25
S Humalog Mix50

06.01.01.03 - Hypodermic equipment

06.01.02 - Antidiabetic drugs

06.01.02.01 - Sulfonylureas

1st gliclazide
1st glibenclamide
1st glimepiride
2nd gliclazide

06.01.02.02 - Biguanides

1st metformin
2nd metformin sachets
2nd metformin modified release

06.01.02.03 - Other antidiabetic drugs

1st saxagliptin (Onglyza)
2nd sitagliptin (Januvia)
2nd Line (including GP use) Linagliptin Consider if declining renal failure
2nd Linagliptin + Metformin
S Vildagliptin

S exenatide
S liraglutide

1st acarbose

2nd pioglitazone

S nateglinide

2nd Dapagliflozin

Formulary Information Position in Diabetic Pathway:

Second line (GP) in combination with metformin as an alternative to a gliptin.
Consider before moving to a GLP-1 where weight lose is desirable. (BMI <30).

Third line (Secondary Care and Insulin Initiating GPs) In combination with insulin

Monitoring

Baseline: Check renal function: avoid if eGFR_{ML/min/1.73m²}

Patient counselling required.

Six monthly: Hb1c & weight. Only continue if adequate reductions maintained

06.01.03 - Diabetic ketoacidosis

06.01.04 - Treatment of hypoglycaemia

1st glucose

1st glucagon

Downloaded from: <http://hywelddahb.inform.wales.nhs.uk/> 5th December 2013